SSTR2 and pancreatic insulinoma: A testament to the importance of SSTR2 in the case of NET treatment is the case of advanced insulinomas, which typically have a low SSTR2 expression and are therefore less or non-responsive to octreotide treatment, demonstrating that SSTR expression is a critical factor in treatment effectiveness [273].